- Home
- TCRT vs REVB Comparison
TCRT vs REVB Comparison
Compare TCRT & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- REVB
- Stock Information
- Founded
- TCRT 1998
- REVB 2020
- Country
- TCRT United States
- REVB United States
- Employees
- TCRT N/A
- REVB N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- REVB Health Care
- Exchange
- TCRT Nasdaq
- REVB Nasdaq
- Market Cap
- TCRT 3.9M
- REVB 4.4M
- IPO Year
- TCRT N/A
- REVB N/A
- Fundamental
- Price
- TCRT $2.33
- REVB $1.97
- Analyst Decision
- TCRT
- REVB
- Analyst Count
- TCRT 0
- REVB 0
- Target Price
- TCRT N/A
- REVB N/A
- AVG Volume (30 Days)
- TCRT 340.1K
- REVB 815.0K
- Earning Date
- TCRT 08-14-2025
- REVB 11-07-2025
- Dividend Yield
- TCRT N/A
- REVB N/A
- EPS Growth
- TCRT N/A
- REVB N/A
- EPS
- TCRT N/A
- REVB N/A
- Revenue
- TCRT $6,000.00
- REVB N/A
- Revenue This Year
- TCRT $5,680,500.00
- REVB N/A
- Revenue Next Year
- TCRT N/A
- REVB N/A
- P/E Ratio
- TCRT N/A
- REVB N/A
- Revenue Growth
- TCRT N/A
- REVB N/A
- 52 Week Low
- TCRT $1.31
- REVB $1.96
- 52 Week High
- TCRT $6.20
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- TCRT 48.79
- REVB 31.96
- Support Level
- TCRT $2.15
- REVB $2.20
- Resistance Level
- TCRT $2.39
- REVB $2.90
- Average True Range (ATR)
- TCRT 0.22
- REVB 0.21
- MACD
- TCRT 0.08
- REVB -0.08
- Stochastic Oscillator
- TCRT 81.97
- REVB 3.16
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).